Zydus said it has received approval from the US Food and Drug Administration, which allows for a site transfer and manufacturing of the drug at Jarod.
The company said it took nearly 12 years to develop this three-dose vaccine, and the vaccine was found safe in the clinical trials.
The approval by the US Food and Drug Administration is for Vigabatrin tablets of 500 mg strength, Cadila Healthcare said in a regulatory filing.
Zydus Cadila said in a statement that the clinical trial in Australia will study the safety, tolerability, pharmacokinetics and pharmacodynamics in patients...
Zydus Cadila's ZyCoV-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above.
PM Narendra Modi will be meeting representatives of Indian Covid-19 vaccine manufactures including Serum Institute of India, Bharat Biotech and Dr Reddy's...
The company said that it would manufacture the drug at its manufacturing facility at the SEZ, Ahmedabad.
'The aim is to develop a priority list with the focus being on adolescents aged 12-18 years with comorbidities,' Dr N K Arora said.
The company's indigenously developed needle-free three-dose COVID-19 vaccine ZyCoV-D was granted emergency use authorisation (EUA) by the drug regulator on...
Previously, India's central drug authority's expert panel sent recommendations for the vaccine's EUA to the Drugs Controller General of India (DCGI) for final...
'Vaccination drive is going on smoothly. It will get more accelerated in the coming days with the ramping up of production by four more Indian companies,' said...
The ZyCoV-D vaccine has a three-dose regimen and it can be administered through a needle-free system.
The company said the drug will be made available across India through the group’s distribution chain reaching out to government and private hospitals...